stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Return on assets
Lakefront Biotherapeutics - Sponsored ADR's return on assets over the twelve months to 30 June 2026 was 0.00%, down 8.7 percentage points from fiscal 2025 (8.72%). Over the past ten years it has ranged from −30.9% (fiscal 2015) to 8.72% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 8.72% | 6.98 |
| FY2024 | 1.74% | (2.98) |
| FY2023 | 4.72% | 8.85 |
| FY2022 | −4.13% | (2.20) |
| FY2021 | −1.93% | 3.31 |
| FY2020 | −5.24% | (9.19) |
| FY2019 | 3.95% | 6.14 |
| FY2018 | −2.19% | 7.67 |
| FY2017 | −9.86% | (16.93) |
| FY2016 | 7.07% | 37.97 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 46.5% |
| VCEL Vericel Corporation compare | 6.86% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | 0.00% |
| SEPN Septerna, Inc. compare | −4.94% |
| ZYME Zymeworks Inc. compare | −37.3% |
| PVLA Palvella Therapeutics, Inc. compare | −37.7% |
| IMNM Immunome, Inc. compare | −59.0% |
| VERA Vera Therapeutics, Inc. compare | −72.3% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement